NCT00031187 - Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

October 31, 2000

Study Completion Date

July 31, 2003

Conditions

Prostatic Neoplasms

Interventions

DRUG

SGN-15 (cBR96-doxorubicin immunoconjugate)

DRUG

Taxotere (docetaxel)

Trial Locations (11)

Arlington Fairfax Hematology-Oncology, P.C., Arlington

Innovative Medical Research of South Florida, Miami Shores

Broward Oncology Associates, Fort Lauderdale

St. Joseph Mercy Oakland Hospital, Pontiac

Florida Cancer Specialists, Fort Myers

Highlands Oncology Group, Springdale

Arizona Cancer Center, Tucson

West Los Angeles - VA Healthcare Center, Los Angeles

Sharp HealthCare, Sidney Kimmel Cancer Center, San Diego

VA Medical Center of Palo Alto, Palo Alto

Bendheim Cancer Center, Greenwich

All Listed Sponsors

lead

Seagen Inc.

INDUSTRY